E-resources
PDF-
Nakamura, Masakatsu; Otsuka, Toshimi; Hayashi, Ranji; Horita, Tomoe; Ota, Masafumi; Sakurai, Naoko; Takano, Hikaru; Hayashi, Tasuku; Kumagai, Motona; Yamada, Sohsuke; Arisawa, Tomiyasu
Internal Medicine, 2020Journal Article
We herein report the case of a 79-year-old patient with unresectable stage III non-small cell lung cancer who developed immune-related hepatitis caused by durvalumab administration. Durvalumab was administered at 10 mg/kg every two weeks after the treatment with carboplatin (AUC2), paclitaxel (35 mg/m2), and 60 Gy radiation. At the day 208 in which the 14th durvalumab administration was scheduled, the patient was urgently hospitalized due to CTCAE Grade 4 hepatic dysfunction detected during the an outpatient blood sampling test. He was diagnosed with immune-related hepatitis and started on methylprednisolone 60 mg/day. After 51 days, his liver dysfunction improved and he was discharged.
